Chair: R Rizzoli

Members: A Bazzocchi,  E Biver, R Blank, JJ Body, ML Brandi, C Campusano, J Cannata-Andia, M Chakhtoura, C Confavreux, P Ebeling, G El Hajj Fuleihan, A El Maghraoui, J Foldes, C Glüer, G Guglielmi, P Hadji, G Holzer, D Kendler, N Napoli, T de Villiers.

To define and assess the effects on bones following a cancer or cancer treatment.

• Discontinuation of denosumab in women with non-metastatic breast cancer
• Monoclonal gammopathy of undetermined significance (MGUS) and Bone Fragility and fractures
• Bone health in patients with non-metastatic prostate cancer on androgen deprivation therapy (ADT)

1. Marcucci, G., et al. Non-metastatic breast cancer patients discontinuing aromatase inhibitor on denosumab: what next?. Osteoporos Int (2026).
2. Teissonnière, M., et al., Bone Effects of Anti-Cancer Treatments in 2024. Calcif Tissue Int 116, 54 (2025).
3. Kendler, D.L., et al. Osteoporosis management in hematologic stem cell transplant recipients: Executive summary.
   J Bone Oncol . 2021 23;28:100361.
4. Marcucci, G., et al., Bone health in childhood cancer: review of the literature and recommendations for the management of bone health in childhood cancer survivors. Ann Oncol, 2019. 30(6): p. 908-920.
5. Kendler, D.L., et al., Bone management in hematologic stem cell transplant recipients. Osteoporos Int, 2018. 29(12): p. 2597-2610.
6. Cianferotti, L., et al., The prevention of fragility fractures in patients with non-metastatic prostate cancer: a position statement by the international osteoporosis foundation. Oncotarget, 2017. 8(43): p. 75646-75663.
7. Rizzoli, R., et al., Cancer-associated bone disease. Osteoporos Int, 2013. 24(12): p. 2929-53.